Ticker Details
Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
IPO Date:	October 7, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$351.04M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.33 | 3.21%
Avg Daily Range (30 D):	$0.16 | 4.82%
Avg Daily Range (90 D):	$0.12 | 4.38%

Institutional Daily Volume
Avg Daily Volume:	.74M
Avg Daily Volume (30 D):	2.3M
Avg Daily Volume (90 D):	1.57M

Trade Size
Avg Trade Size (Sh.):	161
Avg Trade Size (Sh.) (30 D):	159
Avg Trade Size (Sh.) (90 D):	158

Institutional Trades
Total Institutional Trades:	1,178
Avg Institutional Trade:	$1.57M
Avg Institutional Trade (30 D):	$.8M
Avg Institutional Trade (90 D):	$1.68M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.5M
Avg Closing Trade (30 D):	$4.7M
Avg Closing Trade (90 D):	$4.7M
Avg Closing Volume:	145.94K

News

Feb 24, 2026 @ 12:00 PM Aclaris Therapeutics Initiates Phase 1b Proof-of-C... Source: Na

Nov 25, 2025 @ 1:00 PM Aclaris Therapeutics to Participate in the Piper S... Source: Will Roberts

Sep 9, 2025 @ 11:00 AM Aclaris Therapeutics Announces Late-Breaking Abstr... Source: Aclaris Therapeutics

Aug 27, 2025 @ 12:00 PM Aclaris Therapeutics to Participate in Two Septemb... Source: Will Roberts

May 9, 2025 @ 11:00 AM Aclaris Therapeutics to Participate in the HC Wain... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-1.58	$-.12	$-.13
Diluted EPS	$-1.58	$-.12	$-.13
Revenue	$15.74M	$3.3M	$1.78M
Gross Profit	$13.48M	$2.76M	$1.26M
Net Income / Loss	$-141.68M	$-14.61M	$-15.43M
Operating Income / Loss	$-153.32M	$-17.15M	$-18.41M
Cost of Revenue	$2.26M	$.54M	$.52M
Net Cash Flow	$-22.4M	$-.15M	$-4.96M
PE Ratio